\
&
Contact us
The European Partnership for Virtual Worlds supports research and innovation on immersive digital environments. These environments combine 3D technologies, extended reality, simulation and real time interaction.
At EU level, virtual worlds are seen as enabling technology for industry, healthcare, education, culture, media and public services. This partnership is part of the broader EU policy on Web 4.0 and virtual worlds led by the European Commission.
The partnership was launched in December 2025 and is implemented under Horizon Europe, mainly via Cluster 4 Digital Industry and Space.
The partnership is implemented together with the Virtual Worlds Association, which represents industry, research organisations, universities and other stakeholders.
Founding members include several Flemish organisations such as VRT, KU Leuven and IMEC, alongside many European players from industry and research. Siemens is leading the consortium.
Membership of the Association is open and gives access to networking, agenda setting and early insight into future calls.
The partnership itself does not fund projects directly. Funding is provided through Horizon Europe calls that support the partnership objectives.
These calls typically fund:
Indicative EU funding linked to the partnership is up to around €200 million over the programme period, matched by private investment from partners.
Virtual Worlds topics appear under Horizon Europe Cluster 4 work programmes. The first call appeared in 2025, future calls are expected in the 2026 to 2027 work programme. Applicants should always check the official Funding and Tenders Portal for the latest call texts and deadlines.
The partnership follows a Strategic Research and Innovation Agenda, SRIA.
Key focus areas include:
Aligning a proposal with the SRIA is essential for relevance.
This partnership is relevant if you:
Flanders already has strong players in this domain, which lowers the barrier to entry for new applicants.
Practical next steps:
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
nico.deblauwe@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.